Our study provides foundation for further exploring whether GOLPH3 high gliomas will be more sensitive to anti‐EGFR therapy in clinic and give ideas for developing new possible treatments for individual glioma patients. This evidence concerns the gene GOLPH3 and central nervous system cancer.